Rapid On-Site Next-Generation Sequencing

Non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) are malignancies with numerous actionable mutations. Accurate mutation identification is essential for targeted therapies, highlighting the need for next-generation sequencing (NGS). This study evaluated the Oncomine Precision Assay (OPA) as an alternative to single-gene panel (SGP) and send-out NGS (SO-NGS) testing in NSCLC and CRC. Turnaround time (TAT), quantity not sufficient (QNS) rates, and detection of National Comprehensive Cancer Network recommended alterations were compared.